Brief: Sirnaomics Receives FDA Specific Guidance For Further Development Of STP705
16/04/2024 15:43
April 16 (Reuters) - Sirnaomics Ltd 2257.HK :
* RECEIVED FDA SPECIFIC GUIDANCE FOR FURTHER DEVELOPMENT OF
STP705
FOR TREATMENT OF SQUAMOUS CELL CARCINOMA IN SITU
Further company coverage: 2257.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sirnaomics
See all newsBrief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares
Brief: Sirnaomics Says Poon Hung Fai Appointed As Chairman
Brief: Sirnaomics Posts FY Net Income USD -50.2 Million